FDA's Blood Products Advisory Cmte.
Second day of Sept. 17-18 meeting will take place at Parklawn Building, Conference Rooms G & H, not at Office of Biologics Research, as was previously scheduled. First day will still take place at Office of Biologics Research, located on the NIH campus. Public portions of the meeting will discuss reevaluation methods for persons who are currently deferred from donating blood because of reactive hepatitis B surface antigen tests. Public sessions begin at 9:00 A.M. on Sept. 17 and 8:00 A.M. on Sept. 18.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.